Merck (NYSE: MRK) announced that researchers will present data from clinical trials of its investigational diabetes pipeline, JANUVIA® (sitagliptin), and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE